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cycle [15, 16]. Computer modeling studies support the
feasibility of blocking glycolysis by inhibiting the glyco-
lytic enzymes [17–20]. The sequences and structures of
the glycolytic enzymes from trypanosome and leish-
mania species are often very similar to each other and
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4 Department of Chemistry and Biochemistry affect the human enzymes to a considerably lesser de-
gree [10, 11, 14, 21].University of Washington
Seattle, Washington 98195 The enzyme NAD-dependent glycerol-3-phosphate
dehydrogenase (GPDH, E.C. 1.1.1.8) catalyzes the inter-
conversion of dihydroxy acetone phosphate (DHAP) and
glycerol-3-phosphate (G3P) using NAD as a cosub-Summary
strate. In the bloodstream form of T. brucei, GPDH is
especially important because it is responsible for main-Pathogenic protozoa such as Trypanosome and Leish-
mania species cause tremendous suffering world- taining the NAD/NADH balance in the glycosome by the
oxidation of the NADH produced by glyceraldehyde-3-wide. Because of their dependence on glycolysis for
energy, the glycolytic enzymes of these organisms, phosphate dehydrogenase during glycolysis. Blocking
GPDH would jeopardize ATP production and also leadincluding glycerol-3-phosphate dehydrogenase (GPDH),
are considered attractive drug targets. Using the ade- to the accumulation of DHAP in the glycosome, which
may spontaneously convert to methylglyoxylate, a toxicnine part of NAD as a lead compound, several 2,6-
disubstituted purines were synthesized as inhibitors of compound that reacts nonspecifically with proteins [22,
23]. The importance of this enzyme in Leishmania spe-Leishmania mexicana GPDH (LmGPDH). The electron
densities for the inhibitor 2-bromo-6-chloro-purine cies is yet to be evaluated, owing to the presence of
an active mitochondrion throughout the Leishmania lifebound to LmGPDH using a “conventional” wavelength
around 1 A˚ displayed a quasisymmetric shape. The cycle [24]. GPDH in Leishmania, however, plays an im-
portant role in utilizing the glycerol liberated from neutralanomalous signals from data collected at 1.77 A˚ clearly
indicated the positions of the halogen atoms and re- lipids, especially in amastigote stages, where fatty acids
rather than carbohydrates are predominantly used asvealed the multiple binding modes of this inhibitor.
Intriguing differences in the observed binding modes an energy source [25]. L. mexicana GPDH (LmGPDH)
shares 63% sequence identity with the T. brucei enzymeof the inhibitor between very similarly prepared crys-
tals illustrate the possibility of crystal-to-crystal varia- and could serve as a model for drug design targeting
T. brucei GPDH [25]. The apo and NADH bound struc-tions in protein-ligand complex structures.
tures of LmGPDH were previously determined in our
laboratory [13]. When the amino acid sequences nearIntroduction
the substrate binding sites of L. mexicana and human
GPDH were compared for the possibility of selectivePathogenic protozoa, such as Trypanosoma brucei, the
causative agent of sleeping sickness, and several Leish- inhibitor design, the region close to the adenine part
of NAD(H) showed substantial differences between themania species, responsible for various forms of leish-
maniases, continue to cause tremendous suffering and parasite and host enzymes, whereas the DHAP/G3P
binding site is more highly conserved [13]. In the nextmortality to both people and livestock [1]. Moreover, the
drugs currently in use to treat the diseases are often step toward developing selective inhibitors, 2,6-disub-
stituted purine analogs were synthesized, and some ofseverely hampered by problems like toxicity and resis-
tance [2]. There is therefore an urgent need for more them showed inhibition of T. brucei GPDH with an IC50
of 5 mM. Here we report the crystal structures ofeffective drugs. Our laboratory has been studying the
LmGPDH in complex with 2-fluoro-6-chloro-purine (FCP),glycolytic enzymes of these parasites as drug targets
2-bromo-6-chloro-purine (BCP), and 2-bromo-6-hydroxy-with the aim of inhibiting glycolysis and thereby killing
purine (BOP). These molecules may serve as lead com-the parasites [3–14]. The glycolytic enzymes are attrac-
pounds to explore the adenosine binding pocket oftive drug targets for diseases caused by trypanoso-
LmGPDH.matids since glycolysis is the major source of energy
Determining the exact binding mode of ligands tofor most of these parasites during the mammalian stage
macromolecular targets can be particularly challengingof their life cycle. For example, the bloodstream form
when the ligands are quasisymmetric or adopt multipleof T. brucei is entirely dependent on glycolysis for ATP
binding modes. By carefully selecting wavelengths,production, as it lacks a functional tricarboxylic acid
anomalous differences of light elements in protein crys-
tallographic data sets can be used to locate and orient5 Correspondence: hol@gouda.bmsc.washington.edu
ligands, such as substrate, inhibitor, and metal ions6 Present address: Structural Genomix, San Diego, California 92121.
bound to proteins [26–28]. The position of weak anoma-7 Present address: MediQuest Therapeutics Inc., Seattle, Washing-
ton 98103. lous scatterers can be determined from the Bijvoet
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showed significantly higher inhibition of LmGPDH than
adenine. Before further developing high-affinity inhibi-
tors, the binding modes of three 2,6-dihalogenated pu-
rine compounds (FCP, BCP, and BOP) were determined
by X-ray crystallography to understand the exact bind-
ing modes of these lead compounds. The crystal struc-
tures showed that these three inhibitors are binding gen-
erally in the same region as the adenosine part of NADH,
but the binding mode of each compound differs signifi-
cantly from that of adenosine part of NADH.
Binding Modes of FCP
Figure 1. Model-Unbiased, SigmaA-Weighted Fo-Fc Map of FCP Even though the electron density for the inhibitor FCP
Bound to L. mexicana Glycerol-3-Phosphate Dehydrogenase at in the difference map is clear and significant, closer
2.2 A˚ Contoured at 2.5  inspection revealed that there are two possible orienta-
(A) Orientation 1 and (B) Orientation 2. Carbon, nitrogen, chlorine, tions of the bound FCP that are compatible with the
and fluorine are colored brown, blue, yellow, and green, respectively.
electron density (Figure 1). The position of Cl of theDrawn using MOLSCRIPT [45].
bound FCP can be determined unequivocally since Cl
with its 17 electrons gave rise to the highest peak in the
difference density with a height of 8.2 . With the posi-anomalous difference Fourier map, once reasonably ac-
tion of the Cl fixed, there were two possible ways bycurate phases have been obtained. The ambiguities in
which FCP could fit into the rather symmetrical triangularthe binding modes of inhibitor bound to LmGPDH could
density (Figure 1). Both orientations were independentlybe resolved with the help of the anomalous signal ob-
refined and analyzed. Although one of the orientationstained from Br or Cl atoms that were incorporated in
had slightly lower temperature factors than the other,the inhibitors.
the available data makes it difficult to establish with
certainty the true orientation of this ligand, and it is alsoResults and Discussion
possible that both orientations are present in the crystal.
2,6-Disubstituted Purine as an Inhibitor
of LmGPDH Binding Modes of BCP
BCP was synthesized to solve the ambiguity in the bind-Based on the binding mode of NADH in the crystal struc-
ture of the LmGPDH:NADH complex [13], the purine ring ing mode of FCP by incorporating two heavy atoms (Br
and Cl) to differentiate them from carbons and nitrogens.of NADH was first explored for substitution at the 2
and 6 positions. A small number of 2,6-dihalogenated The structure was first solved using data from the Ad-
vance Light Source (ALS, Berkeley) collected at 0.979 A˚purines with IC50’s of about 5 mM were synthesized and
Figure 2. Electron Densities of the Bound In-
hibitor BCP
(A) Model-unbiased, sigmaA-weighted Fo-Fc
map contoured at 3 (light brown), 5 (violet),
and 7  (red) with conformation A of BCP.
(B and C) Two alternative conformations (con-
formation A, green; conformation B, red) of
BCP bound to L. mexicana GPDH in a model-
unbiased, sigmaA-weighted Fo-Fc map (B)
contoured at 3.5  (light brown) and an anom-
alous difference Fourier map contoured at
4.5  (red) and (C) an anomalous difference
Fourier map contoured at 5.5  (red). Carbon,
nitrogen, chlorine, and bromine are colored
brown, blue, yellow, and pink, respectiv-
ely. Drawn using MOLSCRIPT [45] and
Raster3D [46].
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wavelength. The Fo-Fc density clearly showed the pres- inhibitor as well as for 11 out of 16 sulfurs in the protein,
with 5 noise peaks above 4  (Table 1). The peak heightsence of bound inhibitor, and at 7 , only one peak ap-
peared at the “lower” corner of a triangular density. This of S atoms in the anomalous difference Fourier map are
inversely correlated to the refined B factors (Table 1).peak was taken as the position of the Br atom, because
with its 35 electrons, Br was the heaviest element in the Surprisingly, the highest peak in the anomalous differ-
ence Fourier map was not from one of the anomalousinhibitor (Figure 2A). But the position of Cl, even with
its 17 electrons, was not obvious from the Fo-Fc density scatterers mentioned above. The strongest peak ap-
peared on the surface of the protein close to the sidemaps displayed at various contour levels.
To locate the Cl and establish the precise binding chains of Leu339 and the methylene groups of Arg336
and carbonyl oxygen of Arg336. The distances from themode of the inhibitor, data were collected at the Ad-
vanced Photon Source (APS, Argonne National Labora- center of the peak to the carbons range from 3.9 to 4.3 A˚
and that to the carbonyl oxygen of Arg336 is 3.4 A˚ (Figuretory) using 1.7712 A˚ wavelength X-rays with an overall
redundancy of 12.9 to measure the anomalous signals 3C). When a water molecule is placed in the “mystery”
density, its B factor was refined to 14 A˚2 , suggesting itfrom Br and Cl. The anomalous difference density, calcu-
lated after a few rounds of positional refinement when is not a very heavy element with a strong anomalous
signal at 1.77 A˚ wavelength. There is a spherical Fo-Fcthe R factor had dropped to 21.2%, showed distinct
peaks inside the Fo-Fc density of the inhibitor. When density overlapping the mystery peak in the anomalous
difference density. There is a room for an inhibitor mole-contoured at the 4.4  level, anomalous density was
visible at three positions, one at each corner of the cule at this site, but the Fo-Fc map does not show clear
evidence of this.triangular shaped Fo-Fc density. This suggested that
BCP has two alternative binding modes that are rotated To determine the identity of the mystery peak at the
secondary binding sites, a second data set was col-180 about the Br-C2 bond with the Br at the same
position. The peak height of the anomalous density at lected at 1.77 A˚ wavelength using another crystal pre-
pared in the same way. The resulting Fo-Fc differencethe “upper left” corner was 5.2  and that of the “upper
right” corner was 7.1 . This indicated that binding mode map showed two densities indicating the presence of
two BCP molecules stacked on top of each other, BCP2A (Figures 2B and 2C, green) has a higher occupancy
than binding mode B (Figures 2B and 2C, red). The and BCP3 for the “lower” and “upper” difference densi-
ties, respectively (Figure 3D). There were also anoma-occupancy refinement by CNS [29] showed that binding
mode A has an occupancy of 0.7 and binding mode B lous densities at one corner of the each difference den-
sity with heights of 4.8 and 4.2  for the lower andan occupancy of 0.3, with comparable average B factors
for the alternative conformations. upper difference densities, respectively (Figure 3D). The
distance between the anomalous density of BCP2 and
the mystery peak from the first data set was about 0.4 A˚.
Sulfur Peaks and the Second Binding Site of BCP This binding site is created by symmetry-related mole-
from 1.77 A˚ BCP Data Sets cules. The observed anomalous density in each differ-
When the Bijvoet anomalous difference Fourier map was ence density is thought to be from the Br atom of the
calculated for the LmGPDH:BCP complex, it also inhibitor, but the anomalous density from the Cl atoms
showed peaks from the sulfur atoms of the protein in is not observed, probably because of the relatively low
addition to the halogen atoms of the BCP. The expected occupancy of the molecules.
average ratio |FA|/F can be calculated from the From these observations from the second crystal, a
equation 21/2(NA1/2fA″)/(NP1/2Zeff) [30]. In the case of the possible explanation for the strong anomalous density
LmGPDH:BCP complex, the 18 anomalous scatterers, of the first LmGPDH:BCP crystal is that the BCP mole-
including one Br with fA″  1.640, one Cl with fA″  cule has multiple binding modes spanning the large sec-
0.905 electrons from BCP, and 16 S’s with fA″  0.722 ondary binding site formed between two protein mole-
electrons from the cysteine and methionine residues of cules, with the Br atom positioned where the anomalous
the protein [31, 32], give a value of 2.24% for the ratio density is observed. The precise shape of this binding
of |FA|/F at 1.7712 A˚ wavelength. The experimentally site may determine how many BCP molecules fit into
observed |FA|/F ratio of BCP data is lower or close this cavity, and hence the number of BCP molecules
to the expected value in the resolution range from 50 and the shape of the densities might be very sensi-
to 2.7 A˚ (Figure 3B). The observed ratio increased at tive to small crystal-to-crystal differences and also to
higher resolution, probably owing to the increase in er- the molecular rearrangements during the cryocooling
rors of the FA and F measurements. process.
The anomalous difference Fourier map for the whole
protein region was calculated to 2.7 A˚ resolution using
the data collected at 1.77 A˚ wavelength (Figure 3A). The Binding Mode of BOP
The data for BOP was collected at 0.91942 A˚ to maximizepeak search program PEAKMAX [33] was used to locate
the peaks in the anomalous difference Fourier map. In- the anomalous signal from Br. A peak from the anoma-
lous difference density appeared in the Fo-Fc densityspection of the maps revealed that the anomalous differ-
ence Fourier map calculated between 50–2.7 A˚ showed of BOP, indicating the position of Br in BOP. This anoma-
lous difference peak was clearly visible even at the 10the highest number of peaks that coincide with the
anomalous scatterers while displaying the lowest num-  level and was the only peak in the whole protein region
at this contour level (Figure 4). With only one anomalousber of noise peaks. The map calculated between 50 and
2.7 A˚ showed peaks for the Br and Cl atoms of the scatterer (Br) in BOP, the anomalous difference Fourier
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Figure 3. Anomalous Difference Densities
from the Whole Protein and the Secondary
Binding Site of BCP
(A) The anomalous difference Fourier map
contoured at 4.0  for the whole protein re-
gion calculated from 50 to 2.7 A˚. The peaks
that coincide with anomalous scatterers are
colored red, and those that do not are colored
green. The inhibitor and the side chains of all
cysteine and methionine residues are shown
together with the C model of LmGPDH (B)
statistics of the anomalous signal in the data.
(C) The anomalous difference Fourier map
contoured at 10  (red) and Fo-Fc map con-
toured at 3  (light brown) calculated from 50
to 2.7 A˚ around the unidentified peak from
data set BCP1. The distances from the center
of the unidentified peak and neighboring resi-
dues are indicated. Symmetry mates are
drawn in violet. (D) The anomalous difference
Fourier map contoured at 3.5  (red) and
model-unbiased, sigmaA-weighted Fo-Fc
map contoured at 3  (light brown) calculated
from 50 to 2.5 A˚ from data set BCP2. The two
BCP molecules (BCP2: lower density, BCP3:
upper density) are also shown.
map does not give information whether BOP is adopting of the buried surface area by the program Naccess
alternative binding modes. The Fo-Fc difference density (Department of Biochemistry and Molecular Biology,
seems to indicate only one binding mode where the University College, London) with a probe radius of 1.4 A˚
hydroxyl group at the 6 position is pointing in the same showed that the buried surface areas for BCP conforma-
direction as the Cl of BCP in its preferred conformation tion A, BCP conformation B, BOP, FCP, and the adenine
(Figure 2, orientation A). ring of NADH are 199, 203, 172, 179, and 125 A˚2 , respec-
tively (Figure 5D).
The BCP and BOP molecules bind to LmGPDH inComparison of Binding Modes of Inhibitors
quite similar ways where the purine rings of BCP andwith NADH
BOP are rotated and shifted with respect to the purineThe overall structures of the LmGPDH complexed with
ring of adenosine such that the ring resides deep inNADH, BCP, BOP, and FCP are very similar to each
the cleft with the Br atom at the 2 position reaching aother, and 346 C atoms superpose with rmsd’s ranging
hydrophobic pocket made by W44, I93, and F101. Thisfrom 0.22 to 0.37 A˚. Yet, the side chains of M46 and F97
pocket cannot be completely filled by the adenine ringresidues that make the hydrophobic cleft show flexibility
of NADH due to the constraint from the rest of the NADHand shift as much as 1.0 A˚ upon binding different ligands
molecule. The FCP adopts yet another binding mode,(Figure 5B). When compared to NADH, the three inhibi-
with the Cl atom at the 6 position deep in the clefttors are bound deeper into the hydrophobic cleft, with
pointing toward the protein instead of pointing to thethe halogen atoms occupying a hydrophobic pocket
created by W44, I93, and F101 (Figure 5A). Calculation solvent as in NADH. Despite the differences of the bind-
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Table 1. Results of Peak Searching of a Bijvoet Anomalous Difference Fourier Map and Refined B Factors of the Anomalous Scatterers
from Data Set BCP1
Atom Name Peak Height () B Factor (A˚2 )
Unknown 20.3 17.2
S of Cys203 7.5 17.8
Cl of BCP in conformation A 7.1 52.2
Br of BCP 6.7 68.9
S of Met185 6.4 23.3
S of Cys167 6.0 19.7
Cl of BCP in conformation B 5.2 53.3
S of Met32 5.1 29.3
S of Met319 5.0 21.0
S of Cys123 4.9 22.7
Noise 4.6 –
S of Cys194 4.4 23.0
S of Cys322 4.3 22.3
S of Cys38 4.3 24.9
S of Met225 4.3 35.6
Noise 4.3 –




S of Met235a 3.3 29.6
S of Cys42a 3.2 34.4
S of Met309a 2.8 42.8
S of Met46a 1.1 51.0
S of Cys345a 1.1 55.8
a Below 4  level, more noise peaks occur that are not listed.
ing modes, all three planar inhibitors are confined to the lography can be challenging for various reasons, such
as low resolution of the data, low occupancy of thesame plane between F97 and M46. The N1 atom of BCP
and the N7 atom of FCP make hydrogen bonds with a bound ligand, multiple binding modes, and the quasi-
symmetric shape of the molecule. Anomalous scatter-water molecule that is also coordinated to the backbone
carbonyl oxygen of F97 and backbone amide of F101. ers within the ligand can be used as a tool to locate
and orient the molecule and to establish the bindingThere are significant differences between human and T.
brucei GPDH around the adenosine binding site, which mode. Many biologically active small molecules contain
elements that can give small but significant anomalouscan be exploited for selective inhibitor design (Figure 5C).
signal, such as P, S, Cl, and Br. In the Comprehensive
Medicinal Chemistry database (MDL Information Sys-Significance
tems, San Leandro, CA), about 11% of the drugs con-
tain S and about 16% contain Cl. As illustrated in thisDetermination of the binding mode of small organic
molecules bound to a macromolecule by X-ray crystal- paper, anomalous signals from these elements can
help determine the precise binding mode of small mol-
ecules. Furthermore, by using the different absorption
edges of the elements, one can differentiate elements
that bind in similar environments. Finally, the observed
variations of conventional and anomalous difference
maps derived from similarly prepared crystals are a
reason to be cautious with the interpretation of crystal-
lographic results from a single crystal structure.
Experimental Procedures
Synthesis of 2,6-Disubstituted Adenine Analogs
2-bromo-6-hydroxy-purine (BOP) was made by bromination of com-
mercially available 2-thioxanthine (TCI America) according to a pre-
viously described method [34]. The product was then treated with
POCl3 to give 2-bromo-6-chloro-purine (BCP) [35]. 2-fluoro-6-Figure 4. Electron Densities for the Bound Inhibitor BOP
chloro-purine was made from 2-amino-6-chloro-purine by diazotiza-(A) Model-unbiased, sigmaA-weighted Fo-Fc map of BOP bound to
tion with sodium nitrite in aqueous fluoroboric acid [36].LmGPDH contoured at 2.4  (pink) and the anomalous difference
Fourier map (red) contoured at 10  superimposed with the final
model of BOP. Overexpression and Purification of LmGPDH
Leishmania mexicana glycerol-3-phosphate dehydrogenase(B) The anomalous difference Fourier map (red) contoured at 10 
for the whole protein region drawn with the C model of the LmGPDH (LmGPDH) was overexpressed in E.coli as previously described [37].
The protein was subsequently purified in a single step using aand inhibitor BOP. Carbon, nitrogen, oxygen, and bromine are col-
ored brown, blue, red, and pink, respectively. SPRINT HS20 cation exchange column. The resulting protein was
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Figure 5. Comparison of Binding Modes of NADH and Bound Inhibitors
(A) Superposition of NADH, FCP, BCP, and BOP from corresponding complex structures with LmGPDH. The carbons of NADH are colored
green, FCP cyan, BCP pink, and BOP orange. Nitrogens, oxygen, fluorine, chlorine and bromine are colored blue, red, dark cyan, yellow, and
violet, respectively.
(B) Another view of (A) with the surrounding residue.
(C) Stereoview of the superposition where conserved residues between trypanosomatid (L. mexicana and T. brucei) and human GPDH are
colored green, while residues that are different shown in red. An  helix containing residues 37–48 is also colored red, where an insertion
and considerable sequence differences occur in the human enzymes compared to the trypanosomatid enzymes.
(D) Buried surface area calculated by the program Naccess.
concentrated to 4 mg/ml and dialysed against buffer containing 20 mM glycerol 3-phosphate at 23C. Compounds were dissolved in
DMSO and tested at maximum solubility, keeping DMSO concentra-mM triethanolamine (TEA) (pH 7.2), 4 mM DTT, 1 mM EDTA, and 0.5
mM Pefabloc. tion in the assay at 5%. Reactions were initiated by the addition of
excess T. brucei GPDH, and activity was measured in the direction
of NADH formation by monitoring absorption at 340 nm. ControlInhibition Studies
Assays were performed in a total volume of 0.5 ml reaction mixture reactions were run in 5% DMSO without added inhibitor, and inhibi-
tion was measured as percent of control using the initial velocitiesconsisting of 0.1 M TEA buffer (pH 7.5), 0.60 mM NAD, and 10.27
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Table 2. Data Collection and Refinement Statistics
FCP BOP BCP1 BCP2
Space group P41212 P41212 P41212 P41212
Cell parameters (A˚) A  b  70.3, c  210.9 a  b  70.5, c  211.7 a  b  70.4, c  210.8 a  b  70.4, c  210.9
Resolution (A˚) 2.2 2.5 1.9 2.5
Data processing
Observations 196124 295254 532171 286843
Unique reflections 27686 19175 41189 18150
Redundancy 7.1 15.4 12.9 15.8
I/(I) 27.0 (7.6) 34.4 (4.4) 36.8 (3.1) 5.0 (1.6)
Completeness (%) 99.1 (91.6) 98.9 (98.8) 96.3 (71.7) 98.8 (97.3)
Rmerge 0.064 (0.18) 0.089 (0.62) 0.064 (0.47) 0.099 (0.60)
Refinement
Rmsd from ideality
Bond length (A˚) 0.005 0.010 0.010 0.009
Bond angles (o) 1.14 1.34 1.23 1.56
Rcryst (Rfree) 0.208 (0.242) 0.244 (0.286) 0.204 (0.223) 0.206 (0.231)
Number of atoms
Protein 2606 2602 2606 2606
Waters 160 82 311 81
Inhibitor 11 11 22 44
Aliphatic molecule 15 18 18 18
Average B factors (A˚2)
Main chain 27.3 47.9 26.7 39.7
Side chain 34.9 49.5 29.5 42.2
Water 37.2 47.4 43.5 46.2
Inhibitor 48.4 72.4 53.7 (conformation A) 68.1 (BCP1A)
56.1 (conformation B) 68.5 (BCP1B)
68.2 (BCP2)
86.6 (BCP3)
Aliphatic molecule 38.3 63.2 47.8 61.0
Ramachandran plot:
most favored 93.0 (7.0) 92.6 (7.4) 93.6 (6.4) 94.0 (6.0)
(additionally allowed)
Wavelength (A˚) 0.97930 0.91942 1.7712 1.7712
Beamline ALS 5.0.1 APS 19ID APS 19ID ALS 8.2.1
from 0–2 min. Reactions were run in triplicate, and error limits on signal from Br or Cl can be used in the determination of the orienta-
tion of bound inhibitors. After an extended X-ray absorption finepercent inhibition values are within 10%.
structure (EXAFS) scan for Br, LmGPDH:BOP data were collected
at 0.91942 A˚. For BCP soaked crystal, a 1.7712 A˚ wavelength wasCrystallization of LmGPDH
used for data collection (data set BCP1), because it was the longestCrystals were grown using a sitting drop vapor diffusion method by
accessible wavelength without making any time consuming changesmixing 4 	l of protein solution with 4 	l of reservoir solution com-
to the instrumentation at the beamline. The data were collected forposed of 0.8–0.9 M sodium citrate. Crystals grew to their full size
continuous 200 and 180 sweeps to achieve high overall redundan-in 2 weeks. The crystals were then soaked in a cryo solution con-
cies of 15.4 and 12.9 for LmGPDH:BOP and LmGPDH:BCP, respec-taining the corresponding inhibitor molecules for 24 hr. The cryo
tively, since it has been shown that high redundancy of the data issolutions were made of 20 mM TEA (pH 7.2), 4 mM DTT, 1 mM
critical to utilize the small anomalous signal from light elementsEDTA, 0.9 M sodium citrate, 15% (v/v) ethylene glycol, 10% DMSO,
[40–42]. The crystals were essentially isomorphous to the apo crystaland 90 mM FCP or 60 mM BOP or 40 mM BCP. The crystals were
and were refined with the programs CNS and Refmac5 [43]. Thethen flash frozen and used for data collection under nitrogen stream.
structures of LmGPDH in complex with FCP, BOP, and BCP were
refined to 2.2, 2.5, and 1.9 A˚ resolutions, respectively (Table 2).
Data Collection and Refinement
To clarify the identity of the anomalous peak observed in the first
A data set to a resolution of 2.2 A˚ for the LmGPDH:FCP complex
LmGPDH:BCP structure, another dataset from a different crystal
was collected on the SBC-CAT beam line 19-ID at the Advanced was collected (data set BCP2) to 2.5 A˚ at ALS using a wavelength
Photon Source, Argonne National Laboratory. The data for of 1.7712 A˚. The third data set (BCP2) revealed a secondary binding
LmGPDH:BOP and LmGPDH:BCP complexes were collected to site for BCP, where two molecules of BCP were observed between
2.3 A˚ and 1.9 A˚ resolutions, respectively, at beamline 5.0.1 of the symmetry-related protein molecules. Four BCP molecules were built
Advanced Light Source (ALS) at the Lawrence Berkeley National into the structure: BCP1A and BCP1B for the two alternative confor-
Laboratory. The data were integrated, scaled, and merged with mations in the adenosine binding site and BCP2 and BCP3 for the
HKL2000 and SCALEPACK [38]. Intensities were transformed to two molecules in the secondary binding site. Although this data
amplitudes using TRUNCATE [39]. Since the crystals were isomor- helped to explain the strong anomalous peak observed in BCP1
phous to the previous LmGPDH crystals upon soaking [13], the data set, it did not give as detailed information about the binding
structure of the apo enzyme (1EVY.pdb) was used as the starting modes of the inhibitor at the adenosine binding site, probably be-
point for the structure refinements. After conjugate gradient minimi- cause of the lower resolution of the data. As in the apo structure,
zation and restrained individual B factor refinement using the pro- the initial eight residues, the last nine residues (358–366), and the
gram CNS [29], sigmaA-weighted Fo-Fc maps were calculated for loop region (294–296) of LmGPDH are disordered in the crystal
the three data sets and showed clear density for bound inhibitors. structures and have not been included in the model. A linear satu-
Second data sets for the LmGPDH:BOP and the LmGPDH:BCP rated aliphatic molecule was built into an electron density located
complexes were collected on SBC-CAT beamline 19-ID at the Ad- in a well defined hydrophobic pocket, which also appeared in the
vanced Photon Source (APS) in the Argonne National Laboratory. apo LmGPDH structure [13]. The stereochemistry of the models was
verified using the software package PROCHECK [44].At this time the wavelengths were chosen such that anomalous
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